NR4A3 and neoplasm: Molecular or cytogenetic rearrangement is recurrent (t[4;9] [q13;q31]) in the nuclear receptor subfamily 4, Group A, marker 3 (NR4A3). Wong S et al. and Haller F et al., in their large case series, confirmed a 97-98% specificity for moderate to strong NR4A3 expression in ACiCas. Loss of functional mutation of the CDKN2A/2B gene is also noted in this tumour [19,20].